Xarelto Is The Pharma Watchword In Bayer's 3Q Update

 
• By Lucie Ellis-Taitt
  
blood clot
Bayer targets 2017 regulatory filings for Xarelto in coronary artery and peripheral arterial disease

More from Earnings

More from Business